Sudarshan Pharma Industries announced the resignation of its Chief Financial Officer (CFO), Manoj Lodha, effective August 5, 2025. The company disclosed this information to BSE Limited in compliance with regulatory requirements.

Resignation Details

Manoj Lodha has decided to step down from his position as CFO to pursue a higher strategic role in a different industry/sector. In his resignation letter, Lodha expressed gratitude for the support received during his tenure and extended his best wishes for the company's continued success.

Company's Statement

The company confirmed that Manoj Lodha is not related to any directors of Sudarshan Pharma Industries. This clarification was provided as part of the standard disclosure process.

Transition Process

While the company has not yet announced a successor, it is expected that Sudarshan Pharma Industries will initiate the process of identifying a new CFO to ensure a smooth transition of financial leadership.

About Sudarshan Pharma Industries

Sudarshan Pharma Industries is a pharmaceutical company listed on the Bombay Stock Exchange (BSE). The company's registered office is located at 301, Aura Biplex, Above Kalyan Jewellers, S.V. Road, Borivali (West), Mumbai - 400092.

Investors and stakeholders are advised to monitor official company communications for further updates regarding the CFO transition and any potential impact on the company's financial strategy.

Sudarshan Pharma Industries has reported a remarkable turnaround in its financial performance for the first quarter, showcasing significant improvements across key metrics.

Financial Highlights

• Net Profit: ₹37.00 crore, compared to a loss of ₹12.00 crore in Q1 last year
• Revenue: Grew to ₹140.00 crore from ₹100.00 crore year-over-year
• EBITDA: Surged to ₹10.30 crore from ₹2.00 crore
• EBITDA Margin: Expanded to 7.22% from 1.94%

Strong Revenue Growth

Sudarshan Pharma Industries demonstrated robust revenue growth, with its top line increasing by 40% year-over-year to reach ₹140.00 crore. This substantial growth indicates a significant expansion in the company's market presence and sales performance.

Profitability Turnaround

The most notable aspect of Sudarshan Pharma's Q1 results is the impressive turnaround in profitability. The company swung from a loss of ₹12.00 crore in the same quarter last year to a net profit of ₹37.00 crore, marking a substantial improvement in its bottom line.

EBITDA Performance

The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) showed a remarkable improvement, increasing more than fivefold from ₹2.00 crore to ₹10.30 crore. This significant boost in EBITDA reflects enhanced operational efficiency and cost management.

Margin Expansion

Sudarshan Pharma Industries' EBITDA margin expanded considerably, rising from 1.94% in the previous year to 7.22% in the current quarter. This margin expansion of 528 basis points underscores the company's ability to improve its operational efficiency and profitability.

The strong financial performance across all key metrics indicates that Sudarshan Pharma Industries has successfully implemented strategies to drive growth and improve profitability. The company's ability to turn around its operations and deliver substantial improvements in revenue, EBITDA, and net profit positions it well for future growth in the pharmaceutical sector.